Inhibition of the futalosine pathway for menaquinone biosynthesis suppresses Chlamydia trachomatis infection

Brianne M. Dudiak,Tri M. Nguyen,David Needham,Taylor C. Outlaw,Dewey G. McCafferty
DOI: https://doi.org/10.1002/1873-3468.14223
2021-11-16
FEBS Letters
Abstract:Chlamydia trachomatis, an obligate intracellular bacterium with limited metabolic capabilities, possesses the futalosine pathway for menaquinone biosynthesis. Futalosine pathway enzymes have promise as narrow-spectrum antibiotic targets, but the activity and essentiality of chlamydial menaquinone biosynthesis have yet to be established. In this work, menaquinone-7 (MK-7) was identified as a C. trachomatis-produced quinone through liquid chromatography-tandem mass spectrometry. An immunofluorescence-based assay revealed that treatment of C. trachomatis-infected HeLa cells with the futalosine pathway inhibitor docosahexaenoic acid (DHA) reduced inclusion number, inclusion size, and infectious progeny. Supplementation with MK-7 nanoparticles rescued the effect of DHA on inclusion number, indicating that the futalosine pathway is a target of DHA in this system. These results open the door for menaquinone biosynthesis inhibitors to be pursued in antichlamydial development.
cell biology,biochemistry & molecular biology,biophysics
What problem does this paper attempt to address?